An Open Label, Dose Titration Study of Sevelamer Carbonate dosed Three Times A Day in the control of phosphorus levels in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis
Latest Information Update: 29 Jul 2021
At a glance
- Drugs Sevelamer (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Sanofi Genzyme
- 26 Jul 2020 Status changed from recruiting to completed.
- 05 Jul 2016 New trial record